NCT01886378 - A Study of UX007 (Triheptanoin) in Participants With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2014

Primary Completion Date

August 25, 2016

Study Completion Date

August 25, 2016

Conditions

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Carnitine Palmitoyltransferase (CPT II) DeficiencyVery Long Chain Acyl-CoA Dehydrogenase (VLCAD) DeficiencyLongchain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) DeficiencyTrifunctional Protein (TFP) Deficiency

Interventions

DRUG

UX007

Trial Locations (10)

15224

Children's Hospital of Pittsburgh of UPMC, Pittsburgh

20010

Children's National Medical Center, Washington D.C.

33606

University of Southern Florida, Tampa

37232

Vanderbilt Medical Center, Nashville

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

84132

University of Utah, Salt Lake City

02115

Boston Children's Hospital, Boston

B4 6NH

Birmingham Children's Hospital, Birmingham

WC1N 3BP

National Hospital for Neurology and Neurosurgery, London

WC1N 3JH

Great Ormond Street Hospital, London

All Listed Sponsors

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY